A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands
Introduction: Since 2011, treatment guidelines advise targeted therapy (tyrosine kinase inhibitor, TKI) for patients with activating epidermal growth factor receptor (EGFR) mutations (EGFR+) in non-small cell lung cancer (NSCLC). We describe characteristics, first line treatment and survival of patients diagnosed with EGFR+ NSCLC in a European population, focussing on age, gender and trends over time and compare to the whole group and EGFR-. Methods: All patients with non-squamous NSCLC stage IV, diagnosed 2011–2018, were identified from the population-based Netherlands Cancer Registry (N = 31... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Reihe/Periodikum: | ten Berge , D M H J , Aarts , M J , Groen , H J M , Aerts , J G J V & Kloover , J S 2022 , ' A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands ' , European Journal of Cancer , vol. 165 , pp. 195-204 . https://doi.org/10.1016/j.ejca.2022.01.038 |
Schlagwörter: | /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being / name=SDG 3 - Good Health and Well-being |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28794487 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://pure.eur.nl/en/publications/78fbfc7e-926f-45bc-b80a-509e6d68106e |